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Abstract
Objective:  To  analyze  the  prevalence,  control,  and  management  of  hypertension,  hypercholes-
terolemia,  and  diabetes  mellitus  type  2  (DM2).
Design:  Cross-sectional  analysis  of  all  individuals  attended  in  the  Catalan  primary  care  centers
between  2006  and  2009.
Location:  History  of  cardiovascular  diseases,  diagnosis  and  treatment  of  hypertension,  hyper-
cholesterolemia,  DM2,  lipid  proﬁle,  glycemia  and  blood  pressure  data  were  extracted  from
electronic medical  records.  Age-standardized  prevalence  and  levels  of  management  and  control
were estimated.
Participants:  Individuals  aged  35--74  years  using  primary  care  databases.
Main measures: A  total  of  2,174,515  individuals  were  included  (mean  age  52  years  [SD  11],  47%
men).
Results: Hypertension  was  the  most  prevalent  cardiovascular  risk  factor  (39%  in  women,  41%
in men)  followed  by  hypercholesterolemia  (38%  and  40%)  and  DM2  (12%  and  16%),  respec-
tively. Diuretics  and  angiotensin-converting  enzyme  inhibitors  were  most  often  prescribed  for
hypertension  control  (<140/90  mmHg,  achieved  in  68%  of  men  and  60%  of  women  treated).
Hypercholesterolemia  was  controlled  (low-density  lipoprotein  cholesterol  <130  mg/dl)  in  just
31% of  men  and  26%  of  women  with  no  history  of  cardiovascular  disease,  despite  lipid-lowering
treatment,  primarily  (90%)  with  statins.  The  percentage  of  women  and  men  with  DM2  and  with
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glycated  hemoglobin  <7%  was  64.7%  and  59.2%,  respectively;  treatment  was  predominantly  with
oral hypoglycemic  agents  alone  (70%),  or  combined  with  insulin  (15%).
Conclusions:  Hypertension  was  the  most  prevalent  cardiovascular  risk  factor  in  the  Catalan
population  attended  at  primary  care  centers.  About  two  thirds  of  individuals  with  hypertension
or DM2  were  adequately  controlled;  hypercholesterolemia  control  was  particularly  low.
© 2013  Elsevier  España,  S.L.  All  rights  reserved.
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Prevalencia  y  control  de  factores  de  riesgo  cardiovascular  en  la  población  general:
¿qué  nos  dice  la  historia  clínica  electrónica?
Resumen
Objetivos:  Analizar  la  prevalencia,  control  y  manejo  de  la  hipertensión  arterial,  hipercoles-
terolemia  y  diabetes  mellitus  tipo  2.
Disen˜o: Análisis  transversal  de  todos  los  individuos  atendidos  en  centros  de  atención  primaria
entre 2006  y  2009.
Emplazamiento:  Se  extrajo  de  la  historia  clínica  electrónica  los  antecedentes  de  enfermedad
cardiovascular,  el  diagnóstico  y  tratamiento  de  la  hipertensión  arterial,  hipercolesterolemia,
diabetes  mellitus  tipo  2,  el  perﬁl  lipídico,  la  glicemia  y  la  presión  arterial.  Las  prevalencias  y
las variables  de  manejo  y  control  se  estandarizaron  por  edad.
Participantes:  Individuos  de  35  a  74  an˜os  registrados  en  las  bases  de  datos  de  atención  primaria.
Mediciones  principales: Se  analizaron  registros  de  2.174.515  de  individuos  (47%  hombres,  edad
media 52  an˜os  (DE  11)).
Resultados:  La  hipertensión  arterial  fue  el  factor  de  riesgo  más  prevalente  (39%  en  mujeres
y 41%  en  hombres),  seguido  de  la  hipercolesterolemia  (38%  y  40%)  y  la  diabetes  mellitus
tipo 2  (12%  y  16%),  respectivamente.  Los  diuréticos  y  los  inhibidores  de  la  enzima  convertidora
de angiotensina  fueron  los  fármacos  más  frecuentemente  recetados  para  el  control  de  la  presión
arterial (68%  de  hombres  y  60%  de  mujeres  presentaron  valores  <140/90  mmHg).  Sólo  el  31%  de
los hombres  y  el  26%  de  las  mujeres  sin  antecedentes  de  enfermedad  cardiovascular  presentaron
hipercolesterolemia  controlada  (colesterol  de  las  lipoproteínas  de  baja  densidad  <130  mg/dl),
a pesar  del  porcentaje  de  tratamiento  con  estatinas  (90%).  EL  porcentaje  de  mujeres  y  hombres
con diabetes  mellitus  tipo  2  y  hemoglobina  glicada  <7%  era  de  64.7%  y  59.2%,  respectivamente;
el tratamiento  se  realizó  predominantemente  con  antidiabéticos  orales  únicamente  (70%)  o
asociados con  insulina  (15%).
Conclusiones:  La  hipertensión  arterial  fue  el  factor  de  riesgo  cardiovascular  más  prevalente
en población  catalana  atendida  en  centros  de  atención  primaria.  Alrededor  de  dos  tercios
de los  individuos  con  hipertensión  arterial  o  diabetes  mellitus  tipo  2  estaban  adecuadamente
controlados;  mientras  que  el  control  de  la  hipercolesterolemia  fue  especialmente  bajo.
© 2013  Elsevier  Espan˜a,  S.L.  Todos  los  derechos  reservados.
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ardiovascular  disease  (CVD)  causes  56  million  deaths  annu-
lly  all  over  the  world  and  accounts  for  30%  of  recorded
eaths  in  developed  countries.1 In  Spain,  CVD  was  respon-
ible  for  one  fourth  of  all  deaths  recorded  in  2010.2
therosclerosis,  the  common  cause  of  all  CVDs,  has  a  long,
enerally  asymptomatic,  induction  period  that  often  leads
o  an  event  such  as  myocardial  infarction  or  stroke,  with
ore  than  35%  mortality.3 The  control  of  cardiovascular  risk
actors  leads  to  a  reduction  in  CVD  incidence,4 making  pri-
ary  prevention  of  CVD  a  crucial  issue  in  primary  care.
 better  understanding  of  CVD  mechanisms  and  the  role  of
ssociated  risk  factors,  particularly  hypercholesterolemia,
ypertension  and  diabetes  mellitus  type  2  (DM2),  is  essential
o  the  design  and  implementation  of  the  preventive  public
ealth  interventions  that  are  needed.5
Data  routinely  collected  in  primary  care  settings  and
tored  in  electronic  medical  records  (EMR)  databases  have
m
t
t
iecently  been  validated  for  estimating  the  prevalence  of
ardiovascular  risk  factors  in  the  general  population  in
pain.6 The  strengths  of  this  type  of  database  are  mainly
ased  on  the  universal  coverage  of  the  Spanish  National
ealth  System,  which  guarantees  a  representative  popu-
ation,  and  the  collection  of  clinical  and  treatment  data
y  each  individual’s  general  practitioner  and  primary  care
urse,  increasing  data  quality  and  avoiding  the  inaccuracies
nherent  in  self-reported  data.  EMR  in  the  National  Health
ystem  are  stored  in  a  centralized  database  that  can  be
ccessed  by  all  health  professionals.  Recently,  clinical  deci-
ion  support  systems,  such  as  the  electronic  clinical  practice
uidelines,  have  been  integrated  at  several  points  in  the  EMR
oftware.7 A  two-steps  project  has  been  designed  to  ana-
yze  the  impact  of  such  interactive  documents  in  the  clinical
anagement.  The  ﬁrst  phase  of  this  study  aimed  to  analyze
he  prevalence  and  control  of  three  cardiovascular  risk  fac-
ors  (hypercholesterolemia,  hypertension,  and  DM2)  before
mplementing  the  electronic  clinical  practice  guidelines.8
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These  results  can  be  compared  with  previous  epidemiologic
studies  conducted  in  the  same  area.  Indeed,  major  efforts
have  been  made  to  estimate  the  prevalence  of  cardiovascu-
lar  risk  factors  in  Spain  using  general  population  samples
collected  for  research  purposes.9--11 However,  the  use  of
routinely  collected  data  to  create  large  databases  suit-
able  for  research  would  better  optimize  the  large  amount
of  resources  invested  in  our  universal  National  Health  Sys-
tem.
The  objective  of  this  study  is  to  analyze  the  preva-
lence,  control,  and  management  of  hypercholesterolemia,
hypertension,  and  DM2  in  individuals  aged  35--74  years  and
attended  by  primary  care  centers  in  Catalonia  between  2006
and  2009.
Methods
Participants
The  cross-sectional  design  included  all  individuals  aged
35--74  years  attended  in  the  primary  care  centers  of  the
Catalan  Institute  of  Health  from  January  2006  through
December  2009.  The  study  was  conducted  in  Catalonia,  a
Mediterranean  region  in  northeastern  Spain.  The  protocol
of  study  has  been  explained  elsewhere.8
Brieﬂy,  within  Spain’s  National  Health  System  that  serves
every  citizen,  the  Catalan  Institute  of  Health  administers
a  network  of  279  primary  care  centers  that  serves  approx-
imately  80%  of  the  Catalan  population.  Each  individual  is
registered  with  a  primary  care  team  (general  practitioner
and  nurse)  in  one  of  these  publicly  funded  centers.  As  the
main  health  provider  for  Catalonia,  this  network  employs
about  3500  primary  care  physicians  and  serves  5.8  million
patients.12
The  protocol  of  the  present  study  was  approved  by  the
primary  care  research  arm  of  the  Catalan  Institute  of  Health,
the  Institut  d’Investigació  en  Atenció  Primària  Jordi  Gol
Clinical  Research  Ethics  Committee  (authorization  number
P09/28).
Data  management
All  personal  identiﬁers  were  eliminated  before  EMR  data
were  pooled  and  queried  for  patients  seen  between  2006
and  2009.  The  database  contained  the  most  recent  infor-
mation  for  each  patient:  age,  sex,  and  the  International
Classiﬁcation  of  Diseases  (ICD)  codes  for  hypertension,
hypercholesterolemia,  DM2,  coronary  heart  disease,  stroke,
and  peripheral  artery  disease.  If  available,  values  and
dates  for  measurements  of  systolic  and  diastolic  blood
pressure,  total  cholesterol,  low-density  lipoprotein  (LDL)
cholesterol,  high-density  lipoprotein  (HDL)  cholesterol,
triglycerides,  glycemia,  and  glycated  hemoglobin,  along
with  information  regarding  smoking  cessation,  if  applica-
ble.
The  Framingham  risk  score  validated  for  Spain  by  the
Girona  Heart  Registry  researchers  (Framingham-REGICOR)13was  calculated  for  records  containing  complete  data  (age,
sex,  DM2,  systolic  and  diastolic  blood  pressure,  total  choles-
terol,  and  HDL  cholesterol)  and  no  history  of  CVD.  Using
Framingham-REGICOR  risk  charts,  a  cut-off  point  of  10%
C
w
w17
as  used  as  the  indicator  for  hypercholesterolemia  drug
reatment.14
ariables  analyzed
ypertension,  diabetes,  and  hypercholesterolemia  were
dentiﬁed  when  diagnosis  or  treatment  for  these  disorders
as  recorded  between  2006  and  2009.  These  subsamples
f  participants  were  used  for  estimating  the  proportion  of
ontrolled  patients  for  each  disease.  Optimal  control
f  hypertension  was  considered  if  a  record  included  a  sys-
olic  blood  pressure  <140  mmHg  and  diastolic  blood  pressure
90  mmHg  after  diagnosis  or  treatment.  Optimal  control,
uboptimal  control,  and  uncontrolled  diabetes  was  consid-
red  if  an  individual  already  diagnosed  or  treated  presented
ith  glycated  hemoglobin  <7%,  ≥7%  and  <8%  or  ≥8%,
espectively.  Optimal  control  of  hypercholesterolemia  was
onsidered  when  LDL-cholesterol  was  <100  mg/dl  in  patients
ith  CVD  history  or  <130  mg/dl  in  those  with  no  CVD  his-
ory  and  coronary  risk  ≥10%  or  cholesterol-lowering  drug
reatment.
reatment  characterization
he  most  common  groups  of  medications  were  considered:
ntihypertensive  agents  (diuretics,  angiotensin-converting
nzyme  (ACE)  inhibitors,  beta-blockers,  calcium  chan-
el  blockers,  angiotensin  II  receptor  antagonists  (ARA-II),
lpha-blockers,  central  nervous  system  sympatholytics,
nd  direct  acting  vasodilators);  hypoglycemic  agents
biguanide,  sulfonylurea,  alpha-glucosidase  inhibitor,  thi-
zolidinedione,  dipeptidyl  peptidase-4  inhibitors,  other
ral  hypoglycemic  agents  and  insulin);  and  lipid-lowering
rugs  (statins,  ﬁbrates,  ion  exchange  resins,  ezetim-
bes,  other  lipid-lowering  agents).  Within  each  disor-
er,  we  also  described  the  percentage  of  individu-
ls  treated  with  the  most  common  combinations  of
rugs.
tatistical  analysis
revalence  is  presented  by  sex  and  is  standardized  to  the
ge  distribution  of  the  European  population.15 Continu-
us  variables  are  presented  as  mean  and  95%  conﬁdence
nterval  (CI),  and  categorical  variables  as  proportions  and
5%CI.
Missing  values  for  8  variables  (smoking,  total,  LDL  and
DL  cholesterol,  triglycerides,  glucose,  and  systolic
nd  diastolic  blood  pressure)  were  imputed  from  multivari-
te  linear  models  of  every  missing  variable  as  a  function  of
ex,  age,  and  the  rest  of  variables  ﬁtted  by  the  multiple
mputation  method.
Student  T  test  was  used  to  compare  means  of  continuous
ariables  and  Chi-squared  for  proportions.The  R  Statistical  Package  (R  Foundation  for  Statistical
omputing,  Vienna,  Austria;  Version  2.15.0)  and  STATA  soft-
are,  version  12  (Stata  Corp.,  College  Station,  TX,  USA)
ere  used  for  data  analysis.
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Individuals 35-74 years
N=2.174.515
Hypercholesterolemia
Diagnosis or treatment
N=859.159
Hypercholesterolemia
Treatment
N=550.999
Hypertension
Treatment
N=779.797
Hypertension
Diagnosis or treatment
N=887.641
Diabetes Mellitus Type 2
Diagnosis or treatment
N=311.815
Diabetes Mellitus Type 2
Treatment
N=238.726
eneral  outline  of  the  study:  Cross-sectional  design.  All  indi-
iduals  aged  35  to  74  years  attended  in  the  primary  care  centers
f the  Catalan  Institute  of  Health  from  January  2006  through
ecember  2009  were  included.
esults
e  included  2,174,515  individuals,  representing  59%  of  the
atalan  population  aged  35--74  years  (Fig.  1),  and  78%  of
he  total  number  of  these  individuals  assigned  to  primary
are  centers  of  the  Catalan  Institute  of  Health.  The  mean
ge  of  the  sample  was  52  years  (SD  11)  and  47%  were  men;
n  the  assigned  population,  mean  age  was  51  years  (SD  11)
nd  50%  were  men.
Men  were  more  likely  than  women  to  be  smokers  and
o  have  previous  history  of  myocardial  infarction,  stroke
r  peripheral  artery  disease.  The  percentage  of  women
nd  men  with  all  three  risk  factors  (hypertension,  hyper-
holesterolemia  and  DM2)  was  3.6%  and  4.7%,  respectively
Table  1).Hypertension  was  the  most  prevalent  cardiovascular
isk  factor  in  both  sexes.  Although  more  prevalent  in
en,  a  signiﬁcantly  higher  percentage  of  women  were
reated  for  hypertension  and  adequately  controlled.  About
a
6
o
Table  1  Characteristics  of  individuals  included  in  primary  care  
European population.
Age,  mean  (SD)  
Smoking status
Non  smoker,  %  (95%  CI)  
Former smoker,  %  (95%  CI)  
Current smoker,  %  (95%  CI)  
Cardiovascular  riska (%),  mean  (95%  CI)
Cardiovascular  risk  ≥10%a (%),  mean  (95%  CI)
Coronary heart  disease,  %  (95%  CI)
Stroke, %  (95%  CI)  
Peripheral artery  disease,  %  (95%  CI)  
Diagnosed or  treated  for  hypertension,  diabetes  or  hypercholeste
1 risk  factor  
2 risk  factors  
3 risk  factors  
CI, conﬁdence interval.
a Individuals with no history of CVD.A.  Catalán-Ramos  et  al.
alf  of  the  patients  treated  were  taking  one  drug;  18%
f  women  and  21%  of  men  were  treated  with  three  or
ore  drugs.  The  most  common  prescriptions  were  diuret-
cs  (most  often  prescribed  in  women),  ACE  inhibitors  (most
ften  prescribed  in  men),  or  a  combination  of  the  two
rugs  (Table  2).  Among  those  controlled  for  hyperten-
ion,  43.5%  use  one  single  drug,  33.8%  used  two  drugs
nd  the  rest  (22.7%)  were  treated  with  three  or  more
rugs.
Regarding  lipid  proﬁle,  the  non-standardized  median
riglyceride  level  was  100  and  121  mg/dl  in  women  and  men,
espectively  (data  not  shown);  standardized  mean  values
ere  95  and  115  mg/dl.  We  would  also  note  the  high  mean
DL  cholesterol  values  observed  for  women  (60  mg/dl).
ypercholesterolemia  was  the  most  frequent  cardiovascu-
ar  risk  factor  and,  after  diagnosis,  54%  of  women  and
9%  of  men  were  treated  for  this  disorder.  Despite  high
reatment  adequacy  (i.e.,  the  percentage  of  women  and
en  with  cardiovascular  risk  ≥10%  who  received  treat-
ent  was  79%  and  74%,  respectively),  just  26%  of  women
nd  31%  of  men  had  well  controlled  (<130  mg/dl)  LDL-
holesterol.  Furthermore,  the  percentage  of  controlled
ndividuals  with  CVD  history  (LDL-cholesterol  <100  mg/dl)
as  31%  and  43%  in  women  and  men,  respectively.  Statins
as  by  far  the  most  frequently  used  lipid-lowering  agent
Table  3).
Diabetes  mellitus  type  2  was  more  prevalent  in  men
han  in  women,  although  women  were  more  often  treated
nd  a  higher  percentage  achieved  optimal  glycemic  con-
rol  (glycated  hemoglobin  <7%).  In  addition,  60%  and
6%  of  women  and  men  with  diabetes  presented  LDL
holesterol  levels  <130  mg/dl,  respectively.  The  percent-
ges  for  controlled  hypertension  in  this  population  were
9%  for  women  and  63%  for  men.  Approximately  70%
f  treated  individuals  received  oral  hypoglycemic  agents
electronic  medical  records,  by  sex  and  standardized  to  the
Women
N  =  1,144,468
Men
N  =  1,030,047
52  (11)  52  (11)
71.8  (71.7--71.9)  44.8  (44.7--44.9)
9.7  (9.6--9.7)  24.6  (24.5--24.6)
18.6  (18.5--18.6)  30.6  (30.5--30.7)
2.5  (2.5--2.5)  4.3  (4.3--4.3)
1.4  (1.3--1.4) 6.1  (6.0--6.2)
1.6  (1.6--1.7)  5.7  (5.7  --  5.8)
1.2  (1.2--1.2)  2.2  (2.2--2.2)
0.7  (0.7--0.7)  1.9  (1.8--1.9)
rolemia
28.8  (28.7--28.9)  31.2  (31.1--31.2)
14.5  (14.4--14.5)  16.6  (16.6--16.7)
3.6  (3.5--3.6)  4.7  (4.7--4.7)
Prevalence  of  cardiovascular  risk  factors  19
70-74
65-69
60-64
55-59
50-54
45-49
40-44
35-39
70-74
65-69
60-64
55-59
50-54
45-49
40-44
35-39
0 50000 100000 150000 200000
Frequency
Frequency
Ag
e 
gr
ou
ps
Ag
e 
gr
ou
ps
250000 300000 350000
0 50000 100000 150000 200000 250000 300000 350000
Panel A, Study sample
Panel B, Catalonia
Women (N=1,144,468)Men (N=1,030,047)
Women (N=1,839,942)Men (N=1,816,67)
oups
a
w
(
c
f
w
w
f
o
p
iFigure  1  Distribution  of  the  population  by  5-year  age  gr
alone;  15%  received  both  oral  hypoglycemic  agents  and
insulin  (Table  4).
Finally,  17%  out  of  44,481  women  and  19%  out  of
49,115  men  diagnosed  with  all  three  diseases  presented
an  optimal  control  for  all  three  (systolic  and  dias-
tolic  blood  pressure  <140/90  mmHg,  glycated  hemoglobin
<7%  and  LDL-cholesterol  <130  mg/dl  and  <100  mg/dl  for
individuals  in  primary  and  secondary  prevention,  respec-
tively).Discussion
This  analysis  of  more  than  2.1  million  individual  EMR  from
primary  care  centers  in  Catalonia  identiﬁed  hypertension
f
r
m
t in  the  study  sample  (Panel  A)  and  in  Catalonia  (Panel  B).
s  the  most  prevalent  cardiovascular  risk  factor  (38%  in
omen  and  41%  in  men),  followed  by  hypercholesterolemia
37%  and  40%)  and  DM2  (12%  and  16%),  respectively.  The
ontrol  of  cardiovascular  risk  factors  was  acceptable  (>60%)
or  hypertension  and  DM2,  but  low  for  those  diagnosed
ith  hypercholesterolemia  (<40  and  <30%  in  those  with  and
ithout  CVD  history,  respectively).  In  all  cases,  the  most
requently  used  drugs  concurred  with  the  recommendations
f  current  clinical  practice  guidelines.16--18 The  role  of
rimary  care  is  crucial  to  the  control  of  chronic  disorders
n  the  community.  Our  results  indicate  that  there  is  room
or  improvement  in  optimal  control  of  the  cardiovascular
isk  factors,  not  only  at  a  population  level  but  also  in  the
ost  vulnerable  groups,  which  contain  a  high  proportion  of
he  population  CVD  risk.  Population  risk  should  be  based  on
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Table  2  Prevalence  of  hypertension  and  characteristics  of  the  population  diagnosed  with  hypertension,  by  sex  and  standardized
to the  European  population.
Women
N  =  1,144,468
Men
N  =  1,030,047
Systolic  blood  pressure,  mean  (95%  CI)  126  (126--126)  130  (130--130)
Diastolic blood  pressure,  mean  (95%  CI)  76  (76--76)  78  (78--78)
Diagnosed hypertension,  %  (95%  CI)  28.4  (28.4--28.5)  31.9  (31.8--31.9)
Diagnosed or  treated  hypertension,  %  (95%  CI)  38.5  (38.4--38.5)  41.0  (40.9--41.1)
Drug-treated  hypertensionaa,  %  (95%  CI)  87.1  (87.0--87.3)  82.1  (81.9--82.2)
Controlled hypertensionb,  %  (95%  CI)  68.0  (67.8--68.2)  60.0  (59.7--60.2)
Treatments Women
N =  413,930
Men
N  =  365,867
Diuretics,  %  (95%  CI)  53.6  (53.4--53.8)  42.9  (42.7--43.1)
ACE inhibitors,  %  (95%  CI) 42.6  (42.4--42.8) 53.0  (52.8--53.2)
Angiotensin  II  receptor  antagonists,  %  (95%  CI) 22.8  (22.6--22.9) 25.3  (25.1--25.5)
Beta-blockers,  %  (95%  CI) 31.3  (31.1--31.5) 32.7  (32.5--32.9)
Calcium channel  blockers,  %  (95%  CI) 19.7  (19.6--19.9) 24.0  (23.8--24.2)
Alpha-blockers,  %  (95%  CI) 3.3  (3.2--3.3) 6.1  (6.0--6.2)
Central nervous  system  sympatholytics,  %  (95%  CI) 0.5  (0.4--0.5) 0.2  (0.2--0.2)
Direct acting  vasodilators,  %  (95%  CI)  0.4  (0.3--0.4)  0.4  (0.4--0.4)
Treated with  1  drug,  %  (95%  CI)  51.4  (51.2--51.6)  46.8  (46.6--47.0)
Diuretic, %  (95%  CI)  16.1  (15.9--16.2)  7.7  (7.6--7.8)
ACE inhibitor,  %  (95%  CI)  13.4  (13.2--13.5)  18.7  (18.6--18.9)
Angiotensin  II  receptor  antagonist,  %  (95%  CI)  4.6  (4.5--4.7)  5.5  (5.4--5.6)
Beta-blocker,  %  (95%  CI)  12.4  (12.2--12.5)  9.8  (9.7--9.9)
Calcium channel  blocker,  %  (95%  CI)  4.4  (4.3--4.5)  4.2  (4.1--4.3)
Treated with  2  drugs,  %  (95%  CI)  30.8  (30.6--30.9)  32.0  (31.8--32.1)
Diuretic +  ACE  inhibitor,  %  (95%  CI)  10.5  (10.4--10.6)  9.3  (9.2--9.4)
Diuretic +  angiotensin  II  receptor  antagonist,  %  (95%  CI)  5.3  (5.2--5.4)  4.5  (4.4--4.6)
Diuretic +  beta-blocker,  %  (95%  CI)  4.3  (4.2--4.4)  2.9  (2.9--3.0)
Diuretic +  calcium  channel  blocker,  %  (95%  CI)  1.6  (1.6--1.7)  1.2  (1.2--1.2)
ACE inhibitor  +  beta-blocker,  %  (95%  CI)  2.4  (2.3--2.4)  4.4  (4.3--4.4)
ACE inhibitor  +  calcium  channel  blocker,  %  (95%  CI)  1.7  (1.7--1.7)  2.7  (2.7--2.8)
Treated with  ≥3  drugs,  %  (95%  CI)  17.9  (17.7--18.0)  21.3  (21.1--21.4)
a In those diagnosed or treated with hypertension.
b Systolic and diastolic blood pressure <140 mmHg and <90 mmHg, respectively, in individuals under treatment. ACE, angiotensin
converting enzyme; CI, conﬁdence interval.
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she  best  available  methods  (i.e.,  coronary  risk  charts)  to
ocus  public  health  efforts  efﬁciently  while  achieving  the
argest  population  health  beneﬁt.19
omparison  with  previous  studies
he  estimated  prevalence  of  hypertension  and  diabetes
iagnosis  and  treatment  in  our  study  was  similar  to
hat  observed  in  previous  nationwide  epidemiological
tudies.9,10,20 However,  comparisons  for  hypercholesterol-
mia  are  difﬁcult  because  different  thresholds  are  used  to
iagnose  or  treat  this  disorder.9,10,21,22
The  outstanding  mean  value  of  HDL  cholesterol  in  Catalan
omen  (60  mg/dl)  concurs  with  the  DARIOS  Study  results.10
his  protective  factor  may  be  related  to  the  low  incidence
f  myocardial  infarction  observed  in  the  female  population
n  South  Europe,23,24 and  should  considered  in  the  design
c
p
T
cnd  implementation  of  prevention  strategies  in  the  region.
inally,  CVD  risk  should  be  estimated  with  instruments  vali-
ated  for  the  population.25
Notably,  treatment  proﬁles  for  all  three  disorders  stud-
ed  followed  the  recommendations  described  in  the  most
pdated,  evidence-based,  clinical  practice  guidelines.16--18
hese  guidelines  (accessible  via  the  EMR  system)  stan-
ardize  procedures,  reduce  unjustiﬁed  variations  in  clinical
ractice,  and  encourage  physician  behavior  that  promotes
nterventions  supported  by  the  best  evidence  available.26,27
owever,  the  low  control  of  hypercholesterolemia,  as  mea-
ured  with  LDL  cholesterol,  must  be  highlighted.  Despite
tatin  therapy  in  90%  of  individuals  diagnosed  with  hyper-
holesterolemia,  less  than  one  third  of  individuals  requiring
rimary  prevention  of  CVD  had  LDL-cholesterol  <130  mg/dl.
hese  results  were  only  slightly  better  when  we  cal-
ulated  the  proportion  of  individuals  with  history  of
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Table  3  Prevalence  of  hypercholesterolemia  and  characteristics  of  the  population  diagnosed  with  hypercholesterolemia,  by
sex and  standardized  to  the  European  population.
Women
N  =  1,144,468
Men
N  =  1,030,047
Total  cholesterol,  mean  (95%  CI)  210  (210--210)  204  (204--204)
HDL cholesterol,  mean  (95%  CI)  60  (60--60)  49  (49--49)
LDL cholesterol,  mean  (95%  CI)  129  (129--129)  128  (128--128)
Triglycerides,  mean  (95%  CI)  95  (95--95)  115  (115--115)
Prevalence of  diagnosed  and  controlled
hypercholesterolemia
Women
N  =  1,144,468
Men
N  =  1,030,047
Diagnosed  hypercholesterolemia,  %  (95%  CI)  31.3  (31.2--31.4)  32.8  (32.7--32.9)
Hypercholesterolemia  or  treatment,  %  (95%  CI)  37.5  (37.4--37.5)  40.3  (40.3--40.4)
Drug-treated  hypercholesterolemia,  %  (95%  CI)  54.3  (54.1--54.4)  59.3  (59.2--59.5)
Drug-treated  hypercholesterolemia  in  individuals
with  cardiovascular  risk  ≥10%,  %  (95%  CI)
79.1  (71.4--86.9) 74.0  (72.3--75.7)
LDL cholesterol  <130  mg/dl,a %  (95%  CI) 25.6  (25.5--25.8) 31.4  (31.2--31.6)
LDL <100  mg/dl  in  individuals  with  CVD,  %  (95%  CI) 30.6  (29.4--31.9) 43.0  (42.4--43.7)
Characterization  of  hypercholesterolemia  treatment Women
N  =  281,210
Men
N  =  269,789
Statin,  %  (95%  CI)  90.9  (90.7--91.1)  87.2  (87.1--87.4)
Fibrate, %  (95%  CI)  12.0  (11.8--12.2)  20.4  (20.2--20.6)
Ezetimibe, %  (95%  CI)  4.4  (4.2--4.5)  4.9  (4.8--5.0)
Ion exchange  resin,  %  (95%  CI)  1.6  (1.5--1.7)  0.9  (0.8--0.9)
Other lipid-lowering  agents,  %  (95%  CI) 2.4  (2.3--2.5)  3.4  (3.3--3.4)
Treated with  1  drug,  %  (95%  CI)  89.9  (89.7--90.0)  85.4  (85.2--85.6)
Statin, %  (95%  CI)  81.2  (80.9--81.4)  73.3  (73.0--73.5)
Fibrate, %  (95%  CI)  6.1  (5.9--6.2)  10.7  (10.5--10.9)
Ezetimibe, %  (95%  CI)  0.9  (0.8--0.9)  0.5  (0.4--0.5)
Ion exchange  resin,  %  (95%  CI)  1.0  (0.9--1.1)  0.4  (0.4--0.4)
Treated with  2  drugs,  %  (95%  CI)  9.0  (8.9--9.2)  12.7  (12.5--12.8)
Statin +  ﬁbrate,  %  (95%  CI)  4.8  (4.6--4.9)  7.5  (7.4--7.6)
Statin +  ezetimibe,  %  (95%  CI)  2.6  (2.6--2.7)  3.1  (3.0--3.2)
Statin +  ion  exchange  resin,  %  (95%  CI)  0.4  (0.4--0.4)  0.3  (0.2--0.3)
a In individuals treated or with cardiovascular risk ≥10%. CI, conﬁdence interval.
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CCVD  and  LDL-cholesterol  below  the  recommended  thresh-
old  (<100  mg/dl).  Indeed,  the  2004  LIPICAP  Study,  which
included  primary  care  patients  diagnosed  with  hypercholes-
terolemia,  reports  similar  results.28
On  the  other  hand,  the  control  of  hypertension  and
diabetes  was  higher  than  that  previously  reported  and  could
reﬂect  the  implementation  of  more  efﬁcient  strategies
of  controlling  cardiovascular  risk  factors  in  primary  care
settings.29,30 In  our  study,  diuretics  and  ACE  inhibitors  were
the  most  used  antihypertensive  agents,  as  recommended  in
clinical  practice  guidelines.16 However,  ARA-II  was  the  most
frequently  prescribed  in  the  PRESCAP  2006  Study.29 In  addi-
tion,  the  proportion  of  women  with  controlled  hypertension
was  higher  than  in  men.  These  results  concurred  with  those
observed  in  previous  Spanish  population-based  studies.10,31The  high  proportion  of  individuals  controlled  and
treated  with  just  one  drug  for  hypertension  compared
with  previous  studies  could  be  due  to  the  age  of  the
participants  included  (i.e.,  up  to  74  years).32 On  the  other
a
c
p
cand,  biguanide  and  sulfonylurea  were  the  most  frequently
sed  drugs  in  our  study  for  managing  DM2.  The  UKPDS  study
ighlighted  the  effects  of  both  drugs  for  controlling  glucose
evels.33 In  addition,  more  than  40%  of  individuals  with
iabetes  were  treated  with  2  or  more  drugs,  concurring
ith  eControl  study  results  in  Catalonia,  which  included
lmost  290,000  individuals  with  diabetes  mellitus  aged
0--89  years,34 and  with  the  SFIDA  study  conducted  in
taly.35
se  of  primary  care  computerized  registries
or research
omputerization  of  primary  care  EMRs  has  made  avail-
ble  large  volumes  of  routinely  collected  data.  Integrating
linical  decision  support  systems  (e.g.,  electronic  clinical
ractice  guidelines)  in  EMR  should  improve  clinical  out-
omes,  patient  safety,  particularly  important  for  improving
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Table  4  Prevalence  of  diabetes  mellitus  type  2  and  characteristics  of  the  population  diagnosed  with  diabetes  mellitus  type  2,
by sex  and  standardized  to  the  European  population.
Women
N  =  1,144,468
Men
N  =  1,030,047
Glycemia,  mean  (95%  CI)  92  (92--92)  97  (97--97)
Prevalence of  diagnosed  and  controlled  diabetes  Women
N  =  1,144,468
Men
N  =  1,030,047
Diagnosed  diabetes,  %  (95%  CI) 8.8  (8.7--8.8) 13.8  (13.8--13.9)
Diagnosed or  treated  diabetes,  %  (95%  CI) 11.8  (11.7--11.8) 16.2  (16.1--16.2)
Drug-treated  diabetes,  %  (95%  CI) 77.8  (77.5--78.1) 72.2  (71.9--72.4)
Glycated hemoglobin,a %  (95%  CI)  6.8  (6.8--6.8)  7.0  (7.0--7.0)
Glycated hemoglobin  <7%,a %  (95%  CI)  64.7  (64.2--65.1)  59.2  (58.8--59.6)
Glycated hemoglobin  7--7.9%,a %  (95%  CI)  15.3  (15.0--15.7)  17.0  (16.8--17.3)
Glycated hemoglobin  ≥8%,a %  (95%  CI) 20.0  (19.6--20.4) 23.8  (23.4--24.1)
Characterization  of  diabetes  treatment  Women
N  =  113,247
Men
N  =  125,479
Biguanide,  %  (95%  CI) 72.8  (72.4--73.1)  76.4  (76.1--76.7)
Sulfonylurea,  %  (95%  CI) 33.1  (32.7--33.5) 37.2  (36.8--37.5)
Insulin, %  (95%  CI) 30.7  (30.3--31.1)  28.4  (28.1--28.7)
Thiazolidinedione,  %  (95%  CI) 4.6  (4.5--4.8) 4.2  (4.0--4.3)
Alpha-glucosidase  inhibitor,  %  (95%  CI) 3.2  (3.1--3.4)  3.2  (3.1--3.3)
DPP-4 inhibitor,  %  (95%  CI) 2.6  (2.5--2.7) 2.6  (2.5--2.7)
Other hypoglycemic  agents,  %  (95%  CI) 8.9  (8.6--9.1) 7.8  (7.6--8.0)
Oral hypoglycemic  agents,  %  (95%  CI) 69.3  (68.9--69.7) 71.6  (71.3--71.9)
Oral hypoglycemic  agents  and  insulin,  %  (95%  CI) 15.5  (15.3--15.8) 15.6  (15.4--15.9)
Treated with  1  drug,  %  (95%  CI) 60.2  (59.8--60.6) 56.2  (55.9--56.6)
Treated with  2  drugs,  %  (95%  CI) 27.4  (27--27.7) 31.2  (30.9--31.5)
Treated with  ≥3  drugs,  %  (95%  CI) 12.4  (12.2--12.6) 12.6  (12.4--12.8)
CI, conﬁdence interval; DPP-4, dipeptidyl peptidase-4.
a Individuals with treated diabetes.
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ahe  management  of  chronic  diseases.36 In  addition,  avoid
uplication  of  tests,  audit  the  effectiveness  of  care  and
nally  provide  data  for  research.37 Indeed,  an  increasing
umber  of  studies  have  used  EMR  databases  to  assess  the
revalence  and  control  of  cardiovascular  risk  factors.6,38--40
The  results  of  these  studies  may  help  to  improve  both
he  pharmacological  and  non-pharmacological  interven-
ions  recommended  for  CVD  prevention.  The  objective
s  to  increase  the  opportunities  to  avert  or  at  least  slow
own  the  clinical  expression  of  atherosclerosis  in  the
eneral  population.  New  knowledge  may  help  to  produce
vidence-based  documents  to  guide  health  professionals’
ctions.  Indeed,  the  most  recently  released  clinical  practice
uidelines  for  all  three  disorders  described  in  the  present
tudy  (hypercholesterolemia,  hypertension  and  diabetes)
ave  been  integrated  with  our  EMR  system.16--18
haracteristics  and  limitations  of  the  studyhe  present  study  was  conducted  in  primary  care  settings
n  Catalonia.  The  sample  represents  59%  of  the  total  pop-
lation  of  this  area  (and  78%  of  those  attending  Catalan
ealth  Institute  primary  care  centers),  aged  35--74  years.
d
3
b
dlder  individuals  were  excluded  from  analysis  because  we
imed  to  know  the  mean  cardiovascular  risk  of  the  popula-
ion,  which  cannot  be  estimated  by  Framingham  REGICOR
n  those  older  than  75  years.  On  the  one  hand,  individuals
ttended  in  primary  care  could  have  more  pathologies  than
he  non-attended  population.  However,  the  universal  cover-
ge  of  our  public  health  system  minimizes  these  differences.
n  the  other  hand,  the  differences  between  studies  in  the
bserved  prevalences,  estimated  using  the  recorded  diagno-
is  or  diagnosis  and  treatment,  may  reﬂect  some  problems
n  the  quality  of  the  records  used.  However,  in  our  case
he  previous  validation  of  this  database  minimizes  poten-
ial  problems  related  to  underreported  data.6,41 In  addition,
igh-quality  reporting  is  key  not  only  to  ensure  better  quality
f  care  for  patients  but  also  to  improve  databases  that  could
ave  great  potential  for  epidemiological  studies  and  popula-
ion  comparisons.  Further  studies  are  planned  for  analyzing
he  treatments  for  hypertension,  diabetes  mellitus  type  2
nd  hypercholesterolemia  in  depth.
In  conclusion,  hypertension  was  the  most  common  car-
iovascular  risk  factor  in  the  Catalan  population  aged
5--74  years,  followed  by  hypercholesterolemia  and  dia-
etes.  Diuretics  and  ACE  inhibitors  were  the  most  common
rugs  used  to  treat  hypertension;  biguanides  and  statins
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were  most  often  used  for  treating  diabetes  and  hyper-
cholesterolemia,  respectively.  Good  control  was  achieved
in  approximately  two  thirds  of  hypertensive  patients  (68%
of  women  and  66%  of  men),  as  well  as  two  thirds  of
women  and  more  than  half  of  men  diagnosed  with  diabetes
(65%  and  59%);  however,  closer  to  one  third  of  patients,
with  and  without  history  of  CVD,  had  adequately  controlled
hypercholesterolemia.
What is already known?
•  Major  efforts  have  been  made  to  estimate  the  preva-
lence  of  cardiovascular  risk  factors  in  Spain  using
general  population  samples  collected  for  research
purposes.
•  The  use  of  routinely  collected  data  to  create  large
databases  suitable  for  research  could  optimize  the
large  amount  of  resources  invested  in  our  universal
National  Health  System.
What this study adds?
•  Hypertension  was  the  most  prevalent  cardiovascu-
lar  risk  factor,  followed  by  hypercholesterolemia  and
diabetes  mellitus  type  2.
•  The  most  recently  released  clinical  practice  guide-
lines  for  all  three  disorders  have  been  integrated
with  our  electronic  medical  record  system.
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